首页> 外文期刊>Bioconjugate Chemistry >Optimized Methods for the Production and Bioconjugation of Sit-eSpecific, Alkyne-Modified Glucagon-like Peptide-1 (GLP-1) Analogs to Azide-Modified Delivery Platforms Using Copper-Catalyzed Alkyne-Azide Cycloaddition
【24h】

Optimized Methods for the Production and Bioconjugation of Sit-eSpecific, Alkyne-Modified Glucagon-like Peptide-1 (GLP-1) Analogs to Azide-Modified Delivery Platforms Using Copper-Catalyzed Alkyne-Azide Cycloaddition

机译:使用铜催化的炔氧化物环加装入的静止炔丙蛋白样肽-1(GLP-1)类似物的优化方法,静止的炔醇样改性肽-1(GLP-1)类似物到叠氮化物改性的递送平台

获取原文
获取原文并翻译 | 示例
           

摘要

This study aimed to develop and optimize chemistries to produce alkyne-modified glucagon-like peptide-1(7-36)-amide (GLP-1(7-36)-NH2) libraries, which could be rapidly and efficiently conjugated to other components and screened to identify compounds with the best drug delivery properties, as potential treatments for type 2 diabetes or obesity. For this purpose, the Lys26 (K26) side-chain, and the amino (N)-and carboxy (C)-termini of a dipeptidyl peptidase 4 (DPPIV)-resistant GLP-1 sequence (GLP-1(7-36; A8G)-NH2), were modified with an alkyne (4-pentynoic acid or propiolic acid). These analogs were characterized with respect to human GLP-1 receptor (hGLP-1R) agonist activity, effects on cell viability and human serum stability, revealing that these modifications maintained low (N-terminal; EC50 1.5 x 10(-9) M) to subnanomolar (C-terminal and K26, similar to 4 x 10(-10) M) agonist activity toward hGLP-1, had no effect on cell viability, and for the N-terminal and K26 modifications, increased human serum proteolytic stability (t(1/2) > 24 h). Copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction conditions were investigated using the C-terminal modified GLP-1 analog and an azide-modified model lipid peptide, with respect to the effects of altering the azide/alkyne ratio, cosolvents, temperature, reducing agents, Cu(I)-stabilizing ligand, copper source, and the concentrations of reagents/reactants, in order to identify general conditions that provide fast reactions and high yields. A 1:2 azide-alkyne (lipid:GLP-1 peptide) and 4:1 sodium ascorbate/copper sulfate molar ratio in 65% v/v DMSO-water at room temperature, in the absence of Cu(I)-stabilizing ligands (THPTA or L-histidine) and buffers (phosphate, pH 7), provided the best yields. This work reports a library of characterized GLP-1 analogs and chemistries for their attachment to other species, providing useful tools to improve GLP-1 delivery and pharmacology (e.g., through conjugation to other species that lower blood glucose, increase the duration of action, or enable delivery via a nonparenteral route).
机译:本研究旨在开发和优化化学物质以生产炔烃样血糖素样肽-1(7-36) - 酰胺(GLP-1(7-36)-NH2)文库,其可以快速且有效地与其他组分缀合并筛选以鉴定具有最佳药物递送性能的化合物,作为2型糖尿病或肥胖症的潜在治疗方法。为此目的,Lys26(K26)侧链和氨基(N) - 羧基(C) - 二肽肽肽酶4(DPPIV) - 抗生素GLP-1序列(GLP-1(7-36; A8G)-NH2)用炔烃(4-七烯酸或丙醇)改性。这些类似物相对于人GLP-1受体(HGLP-1R)激动剂活性,对细胞活力和人血清稳定性的影响,揭示这些修饰保持低(N-末端; EC50 1.5 x 10(-9)M)对于亚甲醇(C末端和K26,类似于4×10( - 10)m)的激动剂活性对HGLP-1对细胞活力没有影响,并且对于N-末端和K26修饰,增加人血清蛋白水解稳定性( T(1/2)> 24小时)。使用C-末端改性的GLP-1类似物和叠氮化的模型脂质肽研究铜催化的叠氮化物 - 炔环加油(Cuaac)反应条件,相对于改变叠氮化物/炔烃比例,脱水剂,温度,还原剂,Cu(I)-Abilized配体,铜源和试剂/反应物的浓度,以鉴定提供快速反应和高产率的一般条件。 1:2叠氮化物 - 炔(脂质:GLP-1肽)和4:1钠抗坏血酸钠/硫酸铜摩尔比在室温下在65%V / V DMSO-水中,在不存在Cu(I) - 制备配体的情况下(THPTA或L-组氨酸)和缓冲剂(磷酸盐,pH7),提供了最佳产率。这项工作报告了一个特征的GLP-1类似物和化学物质的图书馆,用于将其附着于其他物种,提供有用的工具,以改善GLP-1输送和药理学(例如,通过与降低血糖的其他物种的缀合,增加动作持续时间,增加或通过非乳链状路线能够递送。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号